Skip to main content
. 2024 Sep 12;7(12):e202302041. doi: 10.26508/lsa.202302041

Figure 3. Bone metastatic cancer significantly enhances CGRP levels in serum and plasma.

Figure 3.

Human prostate cancer cell line PC-3, human lung cancer cell line A549, or conditioned medium (sham) was implanted directly into femurs of nude mice. (A) Pain behaviors were measured by guarding behavior measurement. Data are the mean ± SEM. *P ≤ 0.05 versus sham group (t test). (B) CGRP mRNA levels of ipsilateral dorsal root ganglia (L2-L4), (C, D) CGRP secretion in ipsilateral bone marrow, and (D) CGRP levels in serum among cancer-bearing mice and sham-injected mice were measured at week 5 after cancer inoculation. Data are the mean ± SEM. *P ≤ 0.05 versus sham group (t test). (E) Plasma calcitonin gene–related peptide levels of prostate cancer patients without (n = 11) and with (n = 22) bone metastasis. Data are the mean ± SEM. *P ≤ 0.05 versus prostate cancer patients without bone metastasis (t test). (F) CGRP mRNA expression of murine (RM-1) and human (PC3, DU145) prostate cancer cells and dorsal root ganglia using GAPDH as a reference gene and DRG set to 1. Data are the mean ± SEM. ****P ≤ 0.0001 versus DRG (one-way ANOVA, Dunnett’s multiple comparisons).